Marvin & Palmer Associates’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-105,965
Closed -$9.66M 39
2022
Q2
$9.66M Buy
+105,965
New +$9.39M 4.97% 4
2019
Q4
Sell
-67,647
Closed -$5.43M 29
2019
Q3
$5.43M Buy
67,647
+1,670
+3% +$134K 3.57% 21
2019
Q2
$5.28M Sell
65,977
-3,434
-5% -$263K 3.5% 20
2019
Q1
$5.51M Hold
69,411
4.29% 10
2018
Q4
$5.06M Buy
+69,411
New +$4.9M 4.36% 8
2014
Q4
Sell
-20,137
Closed -$1.14M 67
2014
Q3
$1.14M Sell
20,137
-6,343
-24% -$356K 1.16% 39
2014
Q2
$1.46M Buy
+26,480
New +$1.44M 1.27% 38

Other funds holding MRK

Marvin & Palmer Associates's MRK Position: Q3 2022 in Review

Marvin & Palmer Associates sold out of Merck (MRK) in Q3 2022, closing a stake of 105,965 shares — an estimated $9.66M sold.

Marvin & Palmer Associates first reported a position in MRK in Q2 2014 and held it in 7 quarters. The position peaked at $9.66M in Q2 2022. 2,990 funds tracked by Wall St. Rank hold MRK as of Q3 2022.

  • Marvin & Palmer Associates reported no remaining Merck position as of Q3 2022 after selling out during the quarter.
  • Marvin & Palmer Associates sold 105,965 Merck shares in Q3 2022, an estimated $9.66M.
  • Marvin & Palmer Associates first reported a position in Merck in Q2 2014 and held it in 7 quarters.
  • Marvin & Palmer Associates's Merck position peaked at $9.66M in Q2 2022.
  • 2,990 funds tracked by Wall St. Rank held Merck as of Q3 2022.

Based on Marvin & Palmer Associates's 13F filing for Q3 2022, filed 14 Nov 2022.